| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 111 | 2025 | 2401 | 10.180 |
Why?
|
| Islets of Langerhans Transplantation | 90 | 2024 | 748 | 8.860 |
Why?
|
| Graft Survival | 102 | 2024 | 3887 | 5.020 |
Why?
|
| Transplantation Tolerance | 24 | 2022 | 633 | 4.930 |
Why?
|
| Organ Preservation | 24 | 2025 | 393 | 4.180 |
Why?
|
| Kidney Transplantation | 44 | 2024 | 4262 | 3.650 |
Why?
|
| Perfusion | 25 | 2024 | 1401 | 3.330 |
Why?
|
| Graft Rejection | 54 | 2024 | 4492 | 2.950 |
Why?
|
| Tissue Donors | 54 | 2023 | 2381 | 2.770 |
Why?
|
| Transplantation, Heterologous | 39 | 2024 | 2393 | 2.690 |
Why?
|
| Islets of Langerhans | 36 | 2023 | 1351 | 2.520 |
Why?
|
| Tissue and Organ Procurement | 26 | 2022 | 986 | 2.470 |
Why?
|
| Immunosuppressive Agents | 34 | 2024 | 4206 | 2.410 |
Why?
|
| T-Lymphocytes, Regulatory | 24 | 2024 | 3115 | 2.250 |
Why?
|
| Immune Tolerance | 30 | 2022 | 2323 | 2.210 |
Why?
|
| Reperfusion Injury | 9 | 2025 | 1039 | 2.000 |
Why?
|
| Living Donors | 21 | 2024 | 647 | 1.990 |
Why?
|
| Organ Transplantation | 14 | 2023 | 1176 | 1.980 |
Why?
|
| Liver | 39 | 2025 | 7578 | 1.870 |
Why?
|
| Diabetes Mellitus, Type 1 | 36 | 2022 | 3447 | 1.780 |
Why?
|
| Pancreas Transplantation | 14 | 2018 | 193 | 1.760 |
Why?
|
| Organ Preservation Solutions | 6 | 2025 | 104 | 1.570 |
Why?
|
| Transplantation, Homologous | 51 | 2023 | 4834 | 1.570 |
Why?
|
| Carcinoma, Hepatocellular | 16 | 2023 | 2334 | 1.450 |
Why?
|
| Transplants | 3 | 2022 | 208 | 1.430 |
Why?
|
| Isoantigens | 5 | 2016 | 562 | 1.360 |
Why?
|
| Insulin-Secreting Cells | 12 | 2022 | 899 | 1.340 |
Why?
|
| Liver Failure | 9 | 2018 | 252 | 1.310 |
Why?
|
| Waiting Lists | 19 | 2020 | 779 | 1.280 |
Why?
|
| Liver Neoplasms | 16 | 2023 | 4363 | 1.150 |
Why?
|
| Kidney | 17 | 2024 | 7064 | 1.130 |
Why?
|
| Alloys | 2 | 2018 | 111 | 1.120 |
Why?
|
| Antilymphocyte Serum | 10 | 2024 | 492 | 1.090 |
Why?
|
| Skin Transplantation | 16 | 2013 | 1097 | 1.080 |
Why?
|
| End Stage Liver Disease | 6 | 2023 | 370 | 1.020 |
Why?
|
| Titanium | 2 | 2018 | 495 | 0.930 |
Why?
|
| Swine | 21 | 2024 | 5997 | 0.920 |
Why?
|
| Kidney Failure, Chronic | 12 | 2024 | 2496 | 0.890 |
Why?
|
| T-Lymphocytes | 35 | 2024 | 10266 | 0.860 |
Why?
|
| Tacrolimus | 3 | 2023 | 750 | 0.850 |
Why?
|
| Diabetes Mellitus, Experimental | 26 | 2022 | 1124 | 0.830 |
Why?
|
| Brain Death | 6 | 2023 | 359 | 0.800 |
Why?
|
| Blood Substitutes | 2 | 2019 | 57 | 0.800 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 1854 | 0.790 |
Why?
|
| Animals | 163 | 2025 | 169285 | 0.790 |
Why?
|
| Mice, Inbred BALB C | 29 | 2024 | 6231 | 0.750 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2024 | 4415 | 0.700 |
Why?
|
| Cold Ischemia | 5 | 2021 | 72 | 0.700 |
Why?
|
| B-Lymphocytes | 13 | 2021 | 4793 | 0.670 |
Why?
|
| Reoperation | 14 | 2018 | 4329 | 0.670 |
Why?
|
| Transplantation Immunology | 8 | 2013 | 537 | 0.660 |
Why?
|
| Receptors, Interleukin-2 | 5 | 2006 | 564 | 0.660 |
Why?
|
| Liver Failure, Acute | 2 | 2018 | 182 | 0.660 |
Why?
|
| Death | 6 | 2022 | 683 | 0.640 |
Why?
|
| Oxygen | 4 | 2019 | 4270 | 0.640 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2010 | 199 | 0.630 |
Why?
|
| Hemoglobins | 3 | 2019 | 1531 | 0.620 |
Why?
|
| Heat Stroke | 1 | 2018 | 29 | 0.620 |
Why?
|
| Humans | 238 | 2024 | 768171 | 0.610 |
Why?
|
| Silicates | 1 | 2018 | 49 | 0.600 |
Why?
|
| Lymphocyte Transfusion | 3 | 2015 | 232 | 0.600 |
Why?
|
| Temperature | 4 | 2020 | 2234 | 0.600 |
Why?
|
| Primates | 7 | 2023 | 520 | 0.600 |
Why?
|
| Transplantation Chimera | 2 | 2019 | 594 | 0.590 |
Why?
|
| Relaxin | 1 | 2018 | 42 | 0.590 |
Why?
|
| Mice, Inbred C3H | 14 | 2019 | 915 | 0.590 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2010 | 588 | 0.570 |
Why?
|
| Thymus Gland | 15 | 2011 | 1266 | 0.570 |
Why?
|
| Zirconium | 1 | 2018 | 110 | 0.570 |
Why?
|
| Materials Testing | 2 | 2018 | 873 | 0.560 |
Why?
|
| Portal Vein | 4 | 2015 | 435 | 0.550 |
Why?
|
| Nanocomposites | 1 | 2017 | 53 | 0.540 |
Why?
|
| Rats, Inbred Lew | 27 | 2019 | 1163 | 0.530 |
Why?
|
| Major Histocompatibility Complex | 10 | 1995 | 877 | 0.530 |
Why?
|
| Insulin | 22 | 2025 | 6610 | 0.530 |
Why?
|
| Mice | 79 | 2024 | 82049 | 0.510 |
Why?
|
| Mice, Inbred C57BL | 42 | 2024 | 22380 | 0.510 |
Why?
|
| Lymphocyte Activation | 14 | 2022 | 5505 | 0.510 |
Why?
|
| Transplantation | 4 | 2013 | 221 | 0.500 |
Why?
|
| Liver Diseases | 6 | 2015 | 1305 | 0.500 |
Why?
|
| Histocompatibility Antigens | 5 | 2008 | 479 | 0.480 |
Why?
|
| Adenosine Triphosphate | 4 | 2020 | 2004 | 0.470 |
Why?
|
| Hepatitis C | 9 | 2016 | 1595 | 0.470 |
Why?
|
| Hepatic Artery | 4 | 2015 | 232 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 15 | 2017 | 9262 | 0.460 |
Why?
|
| Heart Transplantation | 17 | 2024 | 3301 | 0.460 |
Why?
|
| Cyclosporine | 2 | 2016 | 777 | 0.460 |
Why?
|
| Warm Ischemia | 3 | 2020 | 59 | 0.450 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 318 | 0.440 |
Why?
|
| Chimerism | 2 | 2019 | 156 | 0.430 |
Why?
|
| Motivation | 1 | 2023 | 2020 | 0.420 |
Why?
|
| Biocompatible Materials | 3 | 2018 | 1703 | 0.420 |
Why?
|
| Adenoviridae | 5 | 2011 | 1093 | 0.410 |
Why?
|
| Retrospective Studies | 60 | 2023 | 81760 | 0.410 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2019 | 1816 | 0.400 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 31 | 0.400 |
Why?
|
| Cold Temperature | 6 | 2025 | 791 | 0.390 |
Why?
|
| Male | 124 | 2025 | 364731 | 0.380 |
Why?
|
| Rats | 49 | 2025 | 23782 | 0.380 |
Why?
|
| Autoimmunity | 7 | 2021 | 1361 | 0.380 |
Why?
|
| Cryopreservation | 6 | 2024 | 733 | 0.380 |
Why?
|
| Travel | 2 | 2014 | 805 | 0.380 |
Why?
|
| Neurosurgery | 1 | 2018 | 682 | 0.370 |
Why?
|
| Postoperative Hemorrhage | 2 | 2014 | 419 | 0.370 |
Why?
|
| Histocompatibility Antigens Class II | 10 | 2001 | 1441 | 0.370 |
Why?
|
| Animals, Genetically Modified | 9 | 2024 | 1563 | 0.370 |
Why?
|
| Adoptive Transfer | 6 | 2021 | 825 | 0.360 |
Why?
|
| Triage | 1 | 2018 | 997 | 0.360 |
Why?
|
| Immune System | 2 | 2013 | 800 | 0.360 |
Why?
|
| Interferon-gamma | 6 | 2013 | 3161 | 0.360 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2014 | 241 | 0.360 |
Why?
|
| Hepatectomy | 6 | 2020 | 588 | 0.360 |
Why?
|
| Nephrectomy | 5 | 2017 | 930 | 0.350 |
Why?
|
| Blood Coagulation Factors | 4 | 2017 | 371 | 0.350 |
Why?
|
| Patient Selection | 12 | 2022 | 4260 | 0.350 |
Why?
|
| Adult | 83 | 2024 | 223646 | 0.350 |
Why?
|
| Kidney Function Tests | 3 | 2024 | 684 | 0.350 |
Why?
|
| CD40 Ligand | 4 | 2021 | 528 | 0.340 |
Why?
|
| Alginates | 4 | 2023 | 250 | 0.340 |
Why?
|
| Sirolimus | 5 | 2022 | 1540 | 0.340 |
Why?
|
| Middle Aged | 86 | 2024 | 223487 | 0.340 |
Why?
|
| Donor Selection | 5 | 2023 | 240 | 0.340 |
Why?
|
| Vascular System Injuries | 1 | 2013 | 248 | 0.340 |
Why?
|
| Macaca fascicularis | 5 | 2023 | 912 | 0.340 |
Why?
|
| Mice, Transgenic | 20 | 2022 | 9561 | 0.340 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 283 | 0.340 |
Why?
|
| Blood Glucose | 20 | 2020 | 6431 | 0.330 |
Why?
|
| Chemokine CXCL12 | 4 | 2023 | 457 | 0.330 |
Why?
|
| Lymphocyte Depletion | 9 | 2006 | 605 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2021 | 5717 | 0.330 |
Why?
|
| Pancreatic Ducts | 3 | 2018 | 330 | 0.330 |
Why?
|
| Antigen-Presenting Cells | 8 | 2010 | 960 | 0.320 |
Why?
|
| HLA Antigens | 3 | 2012 | 1334 | 0.320 |
Why?
|
| Health Services Accessibility | 9 | 2018 | 5520 | 0.320 |
Why?
|
| Killer Cells, Natural | 4 | 2017 | 2211 | 0.320 |
Why?
|
| Immunologic Memory | 2 | 2013 | 1377 | 0.310 |
Why?
|
| Lung Transplantation | 2 | 2017 | 1309 | 0.300 |
Why?
|
| Tissue and Organ Harvesting | 5 | 2019 | 373 | 0.300 |
Why?
|
| Laparoscopy | 3 | 2013 | 2041 | 0.300 |
Why?
|
| Postoperative Complications | 19 | 2017 | 15833 | 0.290 |
Why?
|
| Histocompatibility Antigens Class I | 9 | 2010 | 1361 | 0.290 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 170 | 0.290 |
Why?
|
| Female | 99 | 2024 | 397187 | 0.280 |
Why?
|
| Treatment Outcome | 37 | 2021 | 65379 | 0.280 |
Why?
|
| Galactosyltransferases | 3 | 2024 | 284 | 0.280 |
Why?
|
| Melatonin | 1 | 2012 | 670 | 0.280 |
Why?
|
| Raffinose | 3 | 2025 | 57 | 0.270 |
Why?
|
| Kidney Diseases | 4 | 2011 | 2100 | 0.270 |
Why?
|
| Transforming Growth Factor beta | 4 | 2022 | 2004 | 0.270 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 1750 | 0.260 |
Why?
|
| Ablation Techniques | 2 | 2020 | 255 | 0.260 |
Why?
|
| Bone and Bones | 1 | 2017 | 2590 | 0.260 |
Why?
|
| Aspergillus fumigatus | 2 | 2019 | 158 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 9540 | 0.260 |
Why?
|
| Pilot Projects | 5 | 2024 | 8741 | 0.250 |
Why?
|
| Forkhead Transcription Factors | 7 | 2019 | 1625 | 0.250 |
Why?
|
| Papio | 6 | 2018 | 671 | 0.250 |
Why?
|
| Transplantation, Heterotopic | 10 | 2018 | 175 | 0.250 |
Why?
|
| Time Factors | 32 | 2021 | 40220 | 0.240 |
Why?
|
| Rats, Inbred BB | 13 | 1992 | 29 | 0.240 |
Why?
|
| Allopurinol | 3 | 2025 | 202 | 0.240 |
Why?
|
| Tissue Survival | 3 | 2019 | 120 | 0.240 |
Why?
|
| Transgenes | 4 | 2023 | 1016 | 0.230 |
Why?
|
| Lymphocyte Culture Test, Mixed | 5 | 2021 | 510 | 0.230 |
Why?
|
| Risk Factors | 23 | 2023 | 74944 | 0.230 |
Why?
|
| Diabetes Mellitus | 8 | 2023 | 5891 | 0.230 |
Why?
|
| Cells, Cultured | 17 | 2022 | 19025 | 0.230 |
Why?
|
| Mice, Inbred Strains | 6 | 2012 | 1769 | 0.230 |
Why?
|
| Histocompatibility Testing | 7 | 2013 | 716 | 0.230 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 348 | 0.230 |
Why?
|
| Immunity, Innate | 4 | 2022 | 3080 | 0.230 |
Why?
|
| Survival Rate | 18 | 2021 | 12840 | 0.220 |
Why?
|
| Glutathione | 3 | 2025 | 589 | 0.220 |
Why?
|
| Discriminant Analysis | 1 | 2004 | 222 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2014 | 3231 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 2062 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2022 | 7876 | 0.220 |
Why?
|
| Bariatric Surgery | 1 | 2013 | 1001 | 0.220 |
Why?
|
| Economic Competition | 2 | 2016 | 223 | 0.210 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 39354 | 0.210 |
Why?
|
| Macaca mulatta | 3 | 2022 | 2363 | 0.210 |
Why?
|
| Regenerative Medicine | 2 | 2017 | 313 | 0.210 |
Why?
|
| Ischemia | 4 | 2020 | 1900 | 0.200 |
Why?
|
| Antibodies | 5 | 2014 | 2421 | 0.200 |
Why?
|
| United States | 27 | 2023 | 73039 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 9419 | 0.200 |
Why?
|
| Mice, SCID | 8 | 2011 | 2627 | 0.200 |
Why?
|
| Cadaver | 7 | 2013 | 1364 | 0.200 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 56 | 0.200 |
Why?
|
| Prognosis | 12 | 2024 | 30009 | 0.190 |
Why?
|
| Bile Duct Diseases | 2 | 2017 | 98 | 0.190 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2021 | 25 | 0.190 |
Why?
|
| Lymphocytes | 5 | 2009 | 2614 | 0.190 |
Why?
|
| Adenosine | 3 | 2025 | 822 | 0.190 |
Why?
|
| Antigens, Heterophile | 1 | 2001 | 71 | 0.190 |
Why?
|
| Hepatitis B | 3 | 2021 | 711 | 0.180 |
Why?
|
| Dyskeratosis Congenita | 1 | 2021 | 70 | 0.180 |
Why?
|
| Renin | 1 | 2023 | 648 | 0.180 |
Why?
|
| Creatinine | 7 | 2008 | 1918 | 0.180 |
Why?
|
| Rats, Inbred WF | 15 | 1993 | 140 | 0.180 |
Why?
|
| Liver Function Tests | 7 | 2020 | 526 | 0.180 |
Why?
|
| Pancreas | 5 | 2018 | 1699 | 0.180 |
Why?
|
| Health Care Rationing | 2 | 2016 | 435 | 0.180 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 2 | 2010 | 40 | 0.170 |
Why?
|
| C-Peptide | 6 | 2018 | 443 | 0.170 |
Why?
|
| Commerce | 2 | 2016 | 612 | 0.170 |
Why?
|
| Interleukin-10 | 3 | 2013 | 1184 | 0.170 |
Why?
|
| Hypoglycemia | 5 | 2018 | 895 | 0.170 |
Why?
|
| Tumor Necrosis Factors | 2 | 2010 | 109 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 416 | 0.170 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 131 | 0.170 |
Why?
|
| Mice, Inbred NOD | 8 | 2022 | 1837 | 0.170 |
Why?
|
| Liver Regeneration | 2 | 2018 | 214 | 0.170 |
Why?
|
| Blood Cells | 1 | 2021 | 309 | 0.170 |
Why?
|
| Aged | 32 | 2023 | 171502 | 0.170 |
Why?
|
| Renal Insufficiency | 4 | 2017 | 812 | 0.160 |
Why?
|
| Sus scrofa | 1 | 2020 | 430 | 0.160 |
Why?
|
| Proportional Hazards Models | 14 | 2018 | 12543 | 0.160 |
Why?
|
| Genetic Engineering | 3 | 2020 | 936 | 0.160 |
Why?
|
| Aging | 4 | 2013 | 8743 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 1032 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2022 | 588 | 0.160 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 181 | 0.160 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2021 | 897 | 0.160 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 1599 | 0.150 |
Why?
|
| beta 2-Microglobulin | 3 | 1994 | 330 | 0.150 |
Why?
|
| Deoxyglucose | 1 | 2019 | 333 | 0.150 |
Why?
|
| Survival Analysis | 10 | 2020 | 10099 | 0.150 |
Why?
|
| Liver Cirrhosis | 3 | 2018 | 1960 | 0.150 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 1429 | 0.150 |
Why?
|
| Risk Assessment | 11 | 2021 | 24318 | 0.150 |
Why?
|
| Aspergillosis | 2 | 2019 | 242 | 0.150 |
Why?
|
| Immunity, Cellular | 5 | 2015 | 1561 | 0.150 |
Why?
|
| Steroids | 1 | 2023 | 938 | 0.150 |
Why?
|
| Nephritis, Interstitial | 1 | 2019 | 158 | 0.150 |
Why?
|
| Homeostasis | 4 | 2022 | 3348 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 873 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2018 | 93 | 0.150 |
Why?
|
| Coculture Techniques | 1 | 2021 | 1344 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 594 | 0.140 |
Why?
|
| Healthcare Disparities | 5 | 2016 | 3415 | 0.140 |
Why?
|
| Adenine Nucleotides | 1 | 2017 | 110 | 0.140 |
Why?
|
| Kidney Tubules | 1 | 2019 | 454 | 0.140 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 12077 | 0.140 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 145 | 0.140 |
Why?
|
| Porosity | 1 | 2018 | 352 | 0.140 |
Why?
|
| Thrombocytopenia | 2 | 2016 | 1179 | 0.140 |
Why?
|
| Registries | 7 | 2016 | 8375 | 0.140 |
Why?
|
| Renal Dialysis | 6 | 2017 | 1791 | 0.140 |
Why?
|
| Hyperoxaluria, Primary | 1 | 2017 | 25 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2017 | 304 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2003 | 957 | 0.140 |
Why?
|
| Genetic Vectors | 4 | 2004 | 3403 | 0.140 |
Why?
|
| Age Factors | 7 | 2016 | 18415 | 0.140 |
Why?
|
| Swine, Miniature | 4 | 2023 | 965 | 0.140 |
Why?
|
| Gene Transfer Techniques | 4 | 2003 | 1207 | 0.140 |
Why?
|
| Oxalates | 1 | 2017 | 99 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2005 | 1162 | 0.140 |
Why?
|
| Models, Animal | 4 | 2020 | 2122 | 0.140 |
Why?
|
| Regeneration | 4 | 2016 | 1524 | 0.130 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 137 | 0.130 |
Why?
|
| Glucagon | 4 | 2008 | 535 | 0.130 |
Why?
|
| Germ Cells | 1 | 2020 | 644 | 0.130 |
Why?
|
| Length of Stay | 4 | 2016 | 6498 | 0.130 |
Why?
|
| Social Class | 2 | 2016 | 2008 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2008 | 2568 | 0.130 |
Why?
|
| Organ Culture Techniques | 2 | 2017 | 796 | 0.130 |
Why?
|
| Competitive Medical Plans | 1 | 2016 | 26 | 0.130 |
Why?
|
| Immunization, Passive | 4 | 1998 | 619 | 0.130 |
Why?
|
| Elastic Modulus | 1 | 2017 | 211 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 4648 | 0.130 |
Why?
|
| Oxygen Consumption | 2 | 2019 | 1880 | 0.130 |
Why?
|
| Lac Operon | 4 | 2003 | 237 | 0.130 |
Why?
|
| Hypothermia, Induced | 2 | 2020 | 754 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2018 | 6512 | 0.130 |
Why?
|
| Mice, Inbred DBA | 5 | 1995 | 624 | 0.130 |
Why?
|
| Hepatocytes | 3 | 2020 | 1247 | 0.120 |
Why?
|
| Neuroaspergillosis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Streptozocin | 2 | 2015 | 190 | 0.120 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2015 | 221 | 0.120 |
Why?
|
| Resuscitation | 1 | 2020 | 679 | 0.120 |
Why?
|
| Autoimmune Diseases | 9 | 2010 | 2257 | 0.120 |
Why?
|
| Jaundice, Obstructive | 1 | 2015 | 22 | 0.120 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2015 | 24 | 0.120 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 519 | 0.120 |
Why?
|
| Interleukin-2 | 5 | 2011 | 1895 | 0.120 |
Why?
|
| Cell Transplantation | 1 | 2017 | 475 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2006 | 3474 | 0.120 |
Why?
|
| Recovery of Function | 3 | 2008 | 2981 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 197 | 0.120 |
Why?
|
| Contrast Media | 3 | 2015 | 5330 | 0.120 |
Why?
|
| Congresses as Topic | 2 | 2018 | 812 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 306 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 1673 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2004 | 3573 | 0.120 |
Why?
|
| Antigens, CD | 3 | 2021 | 4035 | 0.120 |
Why?
|
| Dextrans | 2 | 2015 | 574 | 0.120 |
Why?
|
| Neutrophils | 2 | 2019 | 3786 | 0.120 |
Why?
|
| Telephone | 1 | 2018 | 630 | 0.120 |
Why?
|
| Recurrence | 8 | 2023 | 8509 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2019 | 6525 | 0.120 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 15453 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2021 | 1758 | 0.110 |
Why?
|
| Genes, MHC Class II | 2 | 1997 | 433 | 0.110 |
Why?
|
| Gene Knockout Techniques | 3 | 2024 | 806 | 0.110 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2014 | 50 | 0.110 |
Why?
|
| Health Care Sector | 1 | 2016 | 196 | 0.110 |
Why?
|
| Liver Circulation | 1 | 2014 | 159 | 0.110 |
Why?
|
| Cell Separation | 8 | 2020 | 1728 | 0.110 |
Why?
|
| Endocrine Glands | 1 | 2013 | 101 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2008 | 4310 | 0.110 |
Why?
|
| Genes, MHC Class I | 1 | 1994 | 235 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2020 | 810 | 0.110 |
Why?
|
| Fluorocarbons | 1 | 2019 | 506 | 0.110 |
Why?
|
| History, 16th Century | 1 | 2013 | 70 | 0.110 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 1397 | 0.110 |
Why?
|
| Immunophenotyping | 3 | 2013 | 1864 | 0.110 |
Why?
|
| Cytokines | 9 | 2023 | 7452 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1997 | 549 | 0.110 |
Why?
|
| Cell Differentiation | 5 | 2018 | 11677 | 0.110 |
Why?
|
| Research Report | 1 | 2016 | 369 | 0.100 |
Why?
|
| Crosses, Genetic | 2 | 2009 | 752 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2021 | 3806 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 660 | 0.100 |
Why?
|
| History, Ancient | 1 | 2013 | 213 | 0.100 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2012 | 222 | 0.100 |
Why?
|
| Medically Underserved Area | 1 | 2015 | 268 | 0.100 |
Why?
|
| Cell Proliferation | 6 | 2019 | 10478 | 0.100 |
Why?
|
| Lymphoid Tissue | 2 | 1993 | 445 | 0.100 |
Why?
|
| Protein S Deficiency | 1 | 2011 | 13 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 1933 | 0.100 |
Why?
|
| Fatal Outcome | 3 | 2016 | 1836 | 0.100 |
Why?
|
| Stem Cells | 3 | 2021 | 3538 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 3 | 2017 | 2227 | 0.100 |
Why?
|
| Constriction, Pathologic | 3 | 2011 | 1104 | 0.100 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2011 | 32 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 2 | 2018 | 809 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 3740 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2016 | 492 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2022 | 23648 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 2015 | 1252 | 0.100 |
Why?
|
| Biological Products | 1 | 2021 | 947 | 0.090 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 733 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 6316 | 0.090 |
Why?
|
| Quality of Life | 3 | 2022 | 13490 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 610 | 0.090 |
Why?
|
| Cholestasis | 1 | 2014 | 385 | 0.090 |
Why?
|
| Heart Arrest | 2 | 2016 | 1515 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2016 | 969 | 0.090 |
Why?
|
| Species Specificity | 5 | 2004 | 2415 | 0.090 |
Why?
|
| Adenovirus Infections, Human | 1 | 2011 | 76 | 0.090 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 216 | 0.090 |
Why?
|
| Endocrine System | 1 | 2011 | 113 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2019 | 1344 | 0.090 |
Why?
|
| Metabolomics | 1 | 2020 | 1674 | 0.090 |
Why?
|
| Microfluidics | 1 | 2015 | 672 | 0.090 |
Why?
|
| Bile Ducts | 1 | 2011 | 288 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2024 | 54924 | 0.090 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 1277 | 0.080 |
Why?
|
| Patient Readmission | 3 | 2016 | 3288 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2125 | 0.080 |
Why?
|
| Gene Expression Regulation | 4 | 2022 | 11930 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 507 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2015 | 761 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2019 | 2418 | 0.080 |
Why?
|
| Antibody Formation | 5 | 1997 | 1393 | 0.080 |
Why?
|
| Cysts | 1 | 2015 | 685 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 823 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2012 | 769 | 0.080 |
Why?
|
| Thrombosis | 1 | 2023 | 2957 | 0.080 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 18349 | 0.080 |
Why?
|
| Autopsy | 1 | 2013 | 1011 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2017 | 1388 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 303 | 0.080 |
Why?
|
| Terminology as Topic | 1 | 2016 | 1542 | 0.080 |
Why?
|
| Acute Disease | 3 | 2015 | 7243 | 0.080 |
Why?
|
| Metabolome | 1 | 2016 | 1009 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 1994 | 1251 | 0.080 |
Why?
|
| Binding, Competitive | 1 | 2010 | 1142 | 0.080 |
Why?
|
| von Willebrand Factor | 1 | 2012 | 680 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 414 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2014 | 1078 | 0.080 |
Why?
|
| Geography | 3 | 2016 | 652 | 0.080 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2008 | 42 | 0.080 |
Why?
|
| Flow Cytometry | 5 | 2013 | 5902 | 0.080 |
Why?
|
| Mice, Knockout | 6 | 2022 | 14488 | 0.080 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 997 | 0.070 |
Why?
|
| Health Resources | 2 | 2004 | 950 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2023 | 15949 | 0.070 |
Why?
|
| Biliary Tract Diseases | 2 | 2011 | 159 | 0.070 |
Why?
|
| Heart-Assist Devices | 2 | 2014 | 1292 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 2237 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2014 | 1309 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2018 | 3968 | 0.070 |
Why?
|
| Glucose | 4 | 2020 | 4352 | 0.070 |
Why?
|
| Delayed Graft Function | 2 | 2022 | 50 | 0.070 |
Why?
|
| Proinsulin | 2 | 2008 | 135 | 0.070 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2015 | 520 | 0.070 |
Why?
|
| Gene Expression | 3 | 1997 | 7601 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 1667 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36741 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 6847 | 0.070 |
Why?
|
| Chemokine CCL5 | 2 | 2019 | 214 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 2 | 2006 | 411 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2077 | 0.070 |
Why?
|
| Phlebography | 1 | 2008 | 326 | 0.070 |
Why?
|
| Heart | 2 | 2019 | 4446 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2013 | 1573 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2019 | 3072 | 0.070 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 331 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1321 | 0.070 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 381 | 0.070 |
Why?
|
| Papio hamadryas | 2 | 2017 | 32 | 0.070 |
Why?
|
| Interleukins | 1 | 2011 | 796 | 0.070 |
Why?
|
| Child | 11 | 2022 | 80917 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 1995 | 1801 | 0.070 |
Why?
|
| Inflammation | 3 | 2011 | 10873 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2907 | 0.060 |
Why?
|
| Cohort Studies | 8 | 2016 | 41753 | 0.060 |
Why?
|
| Incidence | 5 | 2016 | 21538 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 2008 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2023 | 3589 | 0.060 |
Why?
|
| Hepatic Insufficiency | 1 | 2005 | 14 | 0.060 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2006 | 54 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2008 | 374 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2015 | 1554 | 0.060 |
Why?
|
| Glucokinase | 1 | 2006 | 99 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2019 | 12801 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2017 | 3409 | 0.060 |
Why?
|
| Adenoviruses, Human | 2 | 1999 | 257 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2021 | 1667 | 0.060 |
Why?
|
| Pennsylvania | 2 | 2009 | 615 | 0.060 |
Why?
|
| Thiones | 1 | 2025 | 51 | 0.060 |
Why?
|
| Organ Size | 2 | 2015 | 2267 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2011 | 1505 | 0.060 |
Why?
|
| Prediabetic State | 2 | 1988 | 548 | 0.060 |
Why?
|
| Myxoma | 1 | 2005 | 114 | 0.060 |
Why?
|
| Arm | 1 | 2008 | 591 | 0.060 |
Why?
|
| Fistula | 1 | 2006 | 213 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2013 | 2766 | 0.060 |
Why?
|
| Injections | 2 | 2001 | 841 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 291 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 1145 | 0.060 |
Why?
|
| Thymectomy | 3 | 2011 | 200 | 0.060 |
Why?
|
| Cyclosporins | 3 | 1989 | 216 | 0.060 |
Why?
|
| Microscopy, Electron | 2 | 2003 | 2560 | 0.060 |
Why?
|
| Spleen | 5 | 2015 | 2296 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2020 | 1906 | 0.060 |
Why?
|
| Leucine | 1 | 2006 | 547 | 0.060 |
Why?
|
| Minor Lymphocyte Stimulatory Antigens | 2 | 1994 | 10 | 0.060 |
Why?
|
| Intracranial Embolism | 1 | 2005 | 188 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 1134 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2005 | 355 | 0.060 |
Why?
|
| Portal System | 1 | 2003 | 49 | 0.060 |
Why?
|
| Adolescent | 14 | 2018 | 89169 | 0.060 |
Why?
|
| Angioplasty | 1 | 2006 | 356 | 0.060 |
Why?
|
| Organophosphorus Compounds | 1 | 2025 | 211 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2016 | 3466 | 0.050 |
Why?
|
| Immunization | 2 | 2006 | 1219 | 0.050 |
Why?
|
| Hydrogen Sulfide | 1 | 2025 | 147 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 528 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 12252 | 0.050 |
Why?
|
| Injections, Intralymphatic | 1 | 2003 | 15 | 0.050 |
Why?
|
| Ureteral Diseases | 1 | 2003 | 63 | 0.050 |
Why?
|
| Hypoglycemic Agents | 3 | 2018 | 3109 | 0.050 |
Why?
|
| Epitopes | 1 | 2009 | 2527 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2007 | 1826 | 0.050 |
Why?
|
| Forelimb | 1 | 2023 | 116 | 0.050 |
Why?
|
| Hospitals, University | 3 | 1999 | 570 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2010 | 975 | 0.050 |
Why?
|
| Databases, Factual | 4 | 2017 | 8080 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 361 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2018 | 3803 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 3428 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 1997 | 1754 | 0.050 |
Why?
|
| Streptavidin | 1 | 2022 | 81 | 0.050 |
Why?
|
| Radiography | 3 | 2015 | 6986 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 525 | 0.050 |
Why?
|
| Omentum | 1 | 2023 | 168 | 0.050 |
Why?
|
| Bile | 1 | 2003 | 299 | 0.050 |
Why?
|
| International Cooperation | 2 | 2019 | 1436 | 0.050 |
Why?
|
| Kidney Pelvis | 1 | 2003 | 191 | 0.050 |
Why?
|
| Young Adult | 9 | 2021 | 60066 | 0.050 |
Why?
|
| Macrophages | 2 | 2020 | 5802 | 0.050 |
Why?
|
| Biopsy | 4 | 2019 | 6792 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 244 | 0.050 |
Why?
|
| Calcineurin | 1 | 2002 | 235 | 0.050 |
Why?
|
| Equipment Design | 2 | 2020 | 3522 | 0.050 |
Why?
|
| Endoscopy, Digestive System | 1 | 2004 | 358 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2011 | 2167 | 0.050 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2003 | 163 | 0.050 |
Why?
|
| Capsules | 1 | 2021 | 193 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10397 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2003 | 6340 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2003 | 293 | 0.050 |
Why?
|
| Alkaline Phosphatase | 2 | 2011 | 864 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 921 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2008 | 1320 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 348 | 0.050 |
Why?
|
| Cause of Death | 3 | 2017 | 3721 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2005 | 825 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2004 | 899 | 0.050 |
Why?
|
| Lentivirus | 1 | 2004 | 518 | 0.050 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2020 | 61 | 0.040 |
Why?
|
| Apoptosis | 3 | 2025 | 9527 | 0.040 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 100 | 0.040 |
Why?
|
| Hemostasis | 1 | 2023 | 468 | 0.040 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2020 | 63 | 0.040 |
Why?
|
| Hepatitis B virus | 2 | 2021 | 533 | 0.040 |
Why?
|
| Hemodynamics | 3 | 2020 | 4194 | 0.040 |
Why?
|
| Graft Enhancement, Immunologic | 3 | 1990 | 58 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2016 | 3463 | 0.040 |
Why?
|
| Dendritic Cells | 2 | 2022 | 2747 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2003 | 301 | 0.040 |
Why?
|
| Reference Values | 2 | 2005 | 4939 | 0.040 |
Why?
|
| Boston | 3 | 2018 | 9374 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3436 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2006 | 1273 | 0.040 |
Why?
|
| Cell Communication | 1 | 2007 | 1660 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 812 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2004 | 3239 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 3728 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2011 | 1986 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2019 | 50 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2004 | 1480 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2021 | 3140 | 0.040 |
Why?
|
| Ice | 1 | 2020 | 102 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 311 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2020 | 265 | 0.040 |
Why?
|
| Rewarming | 1 | 2019 | 64 | 0.040 |
Why?
|
| Caspases | 1 | 2022 | 882 | 0.040 |
Why?
|
| Culture Techniques | 3 | 1989 | 530 | 0.040 |
Why?
|
| Reassortant Viruses | 1 | 1999 | 36 | 0.040 |
Why?
|
| Cryoprotective Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 10763 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 827 | 0.040 |
Why?
|
| Hepatic Stellate Cells | 1 | 2020 | 117 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2024 | 896 | 0.040 |
Why?
|
| Monocytes | 2 | 2023 | 2605 | 0.040 |
Why?
|
| Models, Biological | 2 | 2014 | 9497 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 13290 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 2907 | 0.040 |
Why?
|
| Kinetics | 2 | 2019 | 6330 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2010 | 2057 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2022 | 1648 | 0.040 |
Why?
|
| Appendicitis | 1 | 2005 | 690 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2024 | 960 | 0.040 |
Why?
|
| Jejunoileal Bypass | 1 | 1998 | 13 | 0.040 |
Why?
|
| Artificial Organs | 1 | 2000 | 149 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2003 | 675 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 991 | 0.040 |
Why?
|
| Probability | 1 | 2004 | 2479 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2021 | 738 | 0.040 |
Why?
|
| Integrin alphaV | 1 | 2018 | 54 | 0.040 |
Why?
|
| Rats, Inbred BN | 4 | 1991 | 231 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1998 | 81 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 229 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2008 | 1459 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 271 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 1997 | 2683 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2023 | 683 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 399 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 341 | 0.040 |
Why?
|
| Hemopneumothorax | 1 | 1997 | 4 | 0.040 |
Why?
|
| Mice, Inbred CBA | 2 | 1995 | 439 | 0.040 |
Why?
|
| Forecasting | 2 | 2017 | 2945 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 297 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2015 | 5107 | 0.040 |
Why?
|
| Cell Survival | 3 | 2010 | 5789 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2003 | 1194 | 0.040 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1997 | 62 | 0.040 |
Why?
|
| Hyperoxaluria | 1 | 2017 | 33 | 0.030 |
Why?
|
| Hemothorax | 1 | 1997 | 58 | 0.030 |
Why?
|
| Lamivudine | 1 | 1998 | 367 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2023 | 1024 | 0.030 |
Why?
|
| Age of Onset | 1 | 2004 | 3346 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2020 | 939 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2017 | 173 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2021 | 5315 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2021 | 1968 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 13013 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1991 | 1353 | 0.030 |
Why?
|
| Mitosis | 1 | 2001 | 1178 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 4 | 2015 | 2709 | 0.030 |
Why?
|
| Pneumothorax | 2 | 1997 | 393 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 866 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 575 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2016 | 2661 | 0.030 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 2087 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 20762 | 0.030 |
Why?
|
| Viral Envelope Proteins | 2 | 2013 | 640 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 1791 | 0.030 |
Why?
|
| Aspergillus flavus | 1 | 2015 | 13 | 0.030 |
Why?
|
| Scedosporium | 1 | 2015 | 10 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2019 | 1643 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 145 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2015 | 150 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 620 | 0.030 |
Why?
|
| Gastroenterology | 1 | 2021 | 593 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 1379 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 630 | 0.030 |
Why?
|
| Aspergillus | 1 | 2015 | 95 | 0.030 |
Why?
|
| California | 1 | 1999 | 1438 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 8142 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2022 | 4585 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1793 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 311 | 0.030 |
Why?
|
| Disease Progression | 4 | 2020 | 13668 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2018 | 3703 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2016 | 9669 | 0.030 |
Why?
|
| Arginine | 2 | 2008 | 932 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 1997 | 288 | 0.030 |
Why?
|
| Atrophy | 1 | 2019 | 1646 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11095 | 0.030 |
Why?
|
| HeLa Cells | 2 | 1997 | 3074 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 864 | 0.030 |
Why?
|
| Receptors, CCR6 | 1 | 2014 | 73 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 14729 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2018 | 42669 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 412 | 0.030 |
Why?
|
| Chimera | 2 | 1993 | 454 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2019 | 1327 | 0.030 |
Why?
|
| Microspheres | 1 | 2017 | 788 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 2227 | 0.030 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 312 | 0.030 |
Why?
|
| H-Y Antigen | 1 | 1993 | 42 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 1230 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 2152 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 414 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1623 | 0.030 |
Why?
|
| Biliary Tract | 1 | 2014 | 135 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1999 | 2923 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2000 | 837 | 0.030 |
Why?
|
| Aurintricarboxylic Acid | 1 | 2012 | 10 | 0.030 |
Why?
|
| Gastrins | 1 | 2013 | 75 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2014 | 240 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2019 | 2089 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 2 | 1993 | 1512 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 283 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2018 | 22290 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2016 | 548 | 0.030 |
Why?
|
| Immunotherapy | 2 | 1988 | 4754 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 794 | 0.030 |
Why?
|
| Venoms | 1 | 2013 | 94 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 3187 | 0.030 |
Why?
|
| North America | 1 | 2016 | 1289 | 0.030 |
Why?
|
| Protein S | 1 | 2011 | 29 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 606 | 0.020 |
Why?
|
| Phenotype | 4 | 2016 | 16726 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1998 | 1217 | 0.020 |
Why?
|
| Complement Activation | 1 | 1994 | 447 | 0.020 |
Why?
|
| Massachusetts | 2 | 2016 | 8890 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2016 | 1049 | 0.020 |
Why?
|
| Fibrosis | 1 | 2019 | 2081 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2020 | 1812 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2012 | 286 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 4355 | 0.020 |
Why?
|
| Organoids | 1 | 2018 | 743 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 5797 | 0.020 |
Why?
|
| Castration | 1 | 2011 | 149 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2011 | 64 | 0.020 |
Why?
|
| Gonads | 1 | 2011 | 109 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1363 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 1126 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3436 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 724 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 4282 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2015 | 445 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1904 | 0.020 |
Why?
|
| Cell Movement | 1 | 2003 | 5213 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 128 | 0.020 |
Why?
|
| Disease Management | 1 | 2021 | 2535 | 0.020 |
Why?
|
| Peptides | 2 | 2013 | 4354 | 0.020 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 347 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2011 | 306 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 1991 | 313 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1997 | 3623 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 365 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2002 | 1942 | 0.020 |
Why?
|
| Plasmids | 1 | 1995 | 2269 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 245 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1999 | 2474 | 0.020 |
Why?
|
| Neck | 1 | 1995 | 736 | 0.020 |
Why?
|
| Rabbits | 1 | 2016 | 4773 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 5196 | 0.020 |
Why?
|
| Antigens | 1 | 2015 | 1443 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 697 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2016 | 1141 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2012 | 577 | 0.020 |
Why?
|
| Bilirubin | 1 | 2011 | 438 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 757 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2018 | 26421 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1982 | 0.020 |
Why?
|
| Leuprolide | 1 | 2011 | 313 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2014 | 809 | 0.020 |
Why?
|
| Triazoles | 1 | 2015 | 904 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1989 | 213 | 0.020 |
Why?
|
| Epithelium | 1 | 2014 | 1607 | 0.020 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2011 | 173 | 0.020 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2015 | 820 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2014 | 1042 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 9384 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2909 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 412 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2010 | 677 | 0.020 |
Why?
|
| Haplotypes | 1 | 1995 | 2722 | 0.020 |
Why?
|
| Th17 Cells | 1 | 2015 | 791 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 3211 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1892 | 0.020 |
Why?
|
| G(M1) Ganglioside | 1 | 1988 | 87 | 0.020 |
Why?
|
| Hemagglutinins | 1 | 2008 | 111 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 1406 | 0.020 |
Why?
|
| Mitochondria | 1 | 2021 | 3683 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 739 | 0.020 |
Why?
|
| Glycosphingolipids | 1 | 1988 | 73 | 0.020 |
Why?
|
| Immune Sera | 1 | 1988 | 605 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2011 | 917 | 0.020 |
Why?
|
| Infant | 3 | 2018 | 36535 | 0.020 |
Why?
|
| Sex Factors | 2 | 2016 | 10632 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2016 | 2507 | 0.020 |
Why?
|
| Zebrafish | 1 | 2019 | 3035 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 2414 | 0.020 |
Why?
|
| Cell Division | 2 | 2010 | 4477 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1987 | 116 | 0.020 |
Why?
|
| Data Collection | 1 | 2016 | 3326 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1530 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2006 | 263 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 381 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 1680 | 0.020 |
Why?
|
| Prednisolone | 1 | 2007 | 326 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2004 | 13053 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 957 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 1810 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1805 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2016 | 2118 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11244 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8542 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3490 | 0.020 |
Why?
|
| beta Catenin | 1 | 2010 | 1047 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 1065 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2008 | 2258 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2005 | 384 | 0.010 |
Why?
|
| NADP | 1 | 2006 | 229 | 0.010 |
Why?
|
| Vincristine | 1 | 2007 | 1040 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2013 | 2874 | 0.010 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2015 | 1673 | 0.010 |
Why?
|
| Aviation | 1 | 2004 | 49 | 0.010 |
Why?
|
| Risk | 1 | 2016 | 9613 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 97 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 696 | 0.010 |
Why?
|
| Veins | 1 | 2008 | 769 | 0.010 |
Why?
|
| Intestinal Perforation | 1 | 2005 | 254 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 104 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1995 | 3124 | 0.010 |
Why?
|
| Universities | 1 | 2009 | 1005 | 0.010 |
Why?
|
| Epinephrine | 1 | 2006 | 794 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3814 | 0.010 |
Why?
|
| Dimerization | 1 | 2005 | 887 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1904 | 0.010 |
Why?
|
| Stents | 1 | 2015 | 3197 | 0.010 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2004 | 176 | 0.010 |
Why?
|
| Insulinoma | 1 | 2003 | 122 | 0.010 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2003 | 76 | 0.010 |
Why?
|
| Fetus | 1 | 1990 | 1883 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 1536 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2011 | 2121 | 0.010 |
Why?
|
| Transportation | 1 | 2004 | 217 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 273 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 611 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14783 | 0.010 |
Why?
|
| Appendectomy | 1 | 2005 | 444 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1994 | 317 | 0.010 |
Why?
|
| Human Growth Hormone | 1 | 2006 | 651 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2005 | 1183 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1988 | 1418 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2227 | 0.010 |
Why?
|
| Cell Line | 2 | 1996 | 15602 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 1169 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2007 | 2234 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 2410 | 0.010 |
Why?
|
| Heart Atria | 1 | 2005 | 1361 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8316 | 0.010 |
Why?
|
| Obesity | 1 | 2021 | 13091 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2005 | 1070 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 9016 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12466 | 0.010 |
Why?
|
| Vascular Fistula | 1 | 1998 | 50 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1998 | 70 | 0.010 |
Why?
|
| Philadelphia | 1 | 1999 | 271 | 0.010 |
Why?
|
| Genotype | 1 | 2013 | 13045 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 59626 | 0.010 |
Why?
|
| Los Angeles | 1 | 1998 | 245 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 1526 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 3620 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1999 | 699 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1998 | 146 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 370 | 0.010 |
Why?
|
| Auscultation | 1 | 1997 | 38 | 0.010 |
Why?
|
| Energy Intake | 1 | 2005 | 2146 | 0.010 |
Why?
|
| Linear Models | 1 | 2007 | 5884 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6124 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1998 | 627 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2011 | 3433 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 14164 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1998 | 855 | 0.010 |
Why?
|
| Brain | 1 | 2022 | 27362 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20225 | 0.010 |
Why?
|
| Wounds, Penetrating | 1 | 1997 | 316 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3713 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 1159 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 5792 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1998 | 742 | 0.010 |
Why?
|
| Proteomics | 1 | 2006 | 3912 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 1998 | 1474 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1998 | 888 | 0.010 |
Why?
|
| Dogs | 1 | 1997 | 3845 | 0.010 |
Why?
|
| Lymphokines | 1 | 1994 | 925 | 0.010 |
Why?
|
| Wounds, Gunshot | 1 | 1997 | 587 | 0.010 |
Why?
|
| Neoplasms | 1 | 2000 | 22371 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 11519 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 2458 | 0.010 |
Why?
|
| Genomics | 1 | 2006 | 5926 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1997 | 1281 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 1999 | 1876 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1993 | 977 | 0.000 |
Why?
|
| Subrenal Capsule Assay | 1 | 1987 | 27 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 7477 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11878 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 2003 | 5442 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3214 | 0.000 |
Why?
|
| Rats, Inbred ACI | 1 | 1983 | 34 | 0.000 |
Why?
|
| Concanavalin A | 1 | 1982 | 190 | 0.000 |
Why?
|
| Thoracic Duct | 1 | 1983 | 71 | 0.000 |
Why?
|
| Lung | 1 | 1997 | 10101 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1982 | 1609 | 0.000 |
Why?
|